Table 4 Effect of any rhG-CSF use on metastasis following postoperative chemotherapy in NSCLC by follow-up 1, 2 and 3 year

 No rhG-CSF

61

4 (6.56%)

1

1

8 (13.11%)

1

1

12 (19.67%)

1

1

 rhG-CSF

246

54 (21.95%)

4.02 (1.45,11.11)

4.44 (1.54,12.79)

80 (32.52%)

3.17 (1.53, 6.58)

2.91 (1.34, 6.29)

101 (41.05%)

2.66 (1.45, 4.86)

2.53 (1.32, 4.82)

 0

61

4 (6.56%)

1

1

8 (13.11%)

1

1

12 (19.67%)

1

1

 ≤ 500

96

19 (19.79%)

3.74 (1.27, 11.01)

4.09 (1.36, 12.34)

32 (33.33%)

3.37 (1.55, 7.33)

3.13 (1.40, 7.00)

41 (42.71%)

2.91 (1.52, 5.57)

2.76 (1.41, 5.43)

 500–1000

85

20 (23.53%)

4.36 (1.49, 12.82)

5.36 (1.70, 16.89)

26 (30.59%)

3.00 (1.35, 6.65)

2.79 (1.18, 6.64)

32 (37.65%)

2.47 (1.29, 4.82)

2.50 (1.20, 5.20)

 1000–1500

32

6 (18.75%)

2.97 (0.84, 10.58)

3.57 (0.96, 13.27)

10 (31.25%)

2.53 (0.99, 6.47)

2.30 (0.87, 6.06)

13 (40.63%)

2.06 (0.93, 4.57)

1.88 (0.82, 4.31)

 > 1500

33

9 (27.27%)

5.21 (1.59, 17.01)

7.18 (1.96, 26.26)

12 (36.36%)

3.88 (1.58, 9.54)

3.88 (1.42, 10.59)

15 (45.45%)

3.18 (1.48, 6.82)

3.12 (1.32, 7.38)

 p for trend

 0

67

5 (7.46%)

1

1

10 (14.93%)

1

1

15 (22.39%)

1

1

 < 15

71

13 (18.31%)

2.52 (0.90, 7.08)

2.91 (0.97, 8.75)

20 (28.17%)

1.97 (0.92, 4.23)

1.89 (0.83, 4.3)

29 (40.85%)

1.83 (0.98, 3.42)

1.79 (0.90, 3.55)

 15–60

89

21 (13.16%)

3.65 (1.37, 9.71)

3.74 (1.31, 10.67)

28 (31.46%)

2.63 (1.27, 5.42)

2.16 (0.98, 4.76)

31 (34.83%)

1.87 (1.01, 3.48)

1.59 (0.80, 3.15)

 60–200

38

5 (13.16%)

2.25 (0.65, 7.84)

1.97 (0.55, 7.15)

11 (28.95%)

2.48 (1.05, 5.88)

1.83 (0.74, 4.51)

16 (42.11%)

2.51 (1.23, 5.12)

1.88 (0.89, 3.97)

 ≥ 200

42

14 (33.33%)

6.13 (2.19, 17.11)

5.88 (2.06, 16.85)

19 (45.24%)

4.97 (2.3, 10.75)

4.18 (1.88, 9.29)

22 (52.38%)

4.09 (2.11, 7.94)

3.38 (1.69, 6.74)

 p for trend

< 0.001

< 0.001